BCL2 and ovarian cancer: A more recent study used ABT737, a compound that inhibits Bcl-2 [189], to activate SIRT3 expression in ovarian cancer, and the results showed that ABT737 enhanced the sensitivity of ovarian cancer cells to cisplatin due to the overexpression of SIRT3 and the regulation of mitochondrial fission [190].